Print logo

FDA is reviewing Novartis's (NOVN VX) Signifor for treatment of Cushing's disease

Reaction details (14:19)

Novartis shares unaffected by the news, last trade at CHF 56.90

Analysis details (14:29)

- FDA advisory panel will meet on 7/11/12 to discuss drug.

05 Nov 2012 - 14:17- Equities- Source: Newswires

Subscribe Now to RANsquawk

Click here for a 1 week free trial

RANsquawk provides audio news and commentary for over 15,000professional traders and brokers worldwide. Services include: